Abstract 13377: Benefit and Risk of Antithrombotic Therapy in Patients With Atrial Fibrillation -A Report From the CHART-2 Study

• Published in: Circulation (New York, N.Y.) N.Y.), 2018-11, Vol.138 (Suppl_1 Suppl 1), p.A13377-A13377
• Main Authors: Shiroto, Takashi, Sakata, Yasuhiko, Nochioka, Kotaro, Abe, Ruri, Oikawa, Takuya, Kasahara, Shintaro, Sato, Masayuki, Aoyanagi, Hajime, Yamanaka, Shinsuke, Fujihashi, Takahide, Miura, Masanobu, Takahashi, Jun, Miyata, Satoshi, Shimokawa, Hiroaki
• Format: Article
• Language: English
• ISSN: 0009-7322; 1524-4539

BackgroundAntithrombotic agents, especially anticoagulants (ACs), are widely used for patients with atrial fibrillation (AF) to prevent thromboembolic events including stroke. However, the efficacy of antithrombotic therapy (ATT) is still occasionally offset by major bleeding complications. In this study, we thus explored the prognostic impact (benefit and risk) of ATT using the database of our Chronic Heart Failure Analysis and Registry in the Tohoku District-2 (CHART-2) Study (N=10,219).Methods and ResultsA total of 3,221 AF patients were examined. They were divided into 4 groups based on ATT at enrollment; no ATT (no-ATT, N=382, mean age 71 yrs.), ACs alone (AC, N=1,101, mean age 70 yrs.), anti-platelets alone (AP, N=824, mean age 73 yrs.), and both of them (AC/AP, N=914, mean age 70 yrs.). With regard to long-term prognosis, all ATT groups had significantly improved all-cause mortality (adjusted hazard ratio (aHR) 0.71, 0.79 and 0.72 for AC, AP and AC/AP, respectively, all P